A Randomized Phase II Study of Cabozantinib Versus Weekly Paclitaxel in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer: an NRG Oncology/Gynecologic Oncology Group Study

INTRODUCTION: Cabozantinib is a receptor tyrosine kinases inhibitor that targets MET (c-MET), VEGF receptor 2 (VEGFR2), RET, AXL, KIT, FLT-3, and TIE-2 and previously showed promising single agent activity in recurrent ovarian cancer. METHODS: This was an open label, 1:1 randomized study of cabozant...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Gynecol Oncol
Hauptverfasser: Matulonis, Ursula A., Sill, Michael W., Makker, Vicky, Mutch, David G., Carlson, Jay W., Darus, Christopher J., Mannel, Robert S., Bender, David P., Crane, Erin K., Aghajanian, Carol
Format: Artigo
Sprache:Inglês
Veröffentlicht: 2018
Schlagworte:
Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6542283/
https://ncbi.nlm.nih.gov/pubmed/30587441
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ygyno.2018.12.008
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge